Treatment options after sorafenib failure in patients with hepatocellular carcinoma.
- Author:
Imane El DIKA
1
;
Ghassan K ABOU-ALFA
Author Information
- Publication Type:Review
- Keywords: Hepatocellular carcinoma; Antiangiogenic therapy; MET-inhibitors; Immunotherapy
- MeSH: Carcinoma, Hepatocellular*; Humans; Immunotherapy; Incidence; Prognosis
- From:Clinical and Molecular Hepatology 2017;23(4):273-279
- CountryRepublic of Korea
- Language:English
- Abstract: Second line therapy after failure of sorafenib continues to be under study. Prognosis of hepatocellular carcinoma is measured in months, with median overall survival reaching 10.7 months with sorafenib. Because of the modest net benefit sorafenib has contributed, and rising incidence of hepatocellular carcinoma in the world, continued efforts are ongoing to look for efficient upfront, second line, or combination therapies. Herein we review the most relevant to date published literature on treatment options beyond sorafenib, reported studies, ongoing investigational efforts, and possibilities for future studies in advanced hepatocellular carcinoma.
